-transparent.png){kind=logo}
Terminal chronic renal failure was discovered in a patient who had received CCNU 1 940 mg/m2 during the previous two years. The renal function was normal before treatment, and there was no evidence of other causes of renal failure. The clinical picture was identical with that observed in patients receiving such treatment and recently published. This case emphasizes the need for limiting the dose of nitrosyl-urea compounds to 1 200 mg/m2 and for monitoring the renal function very closely during and towards the end of the treatment.
Related Publications
A Goupil, and
A Baglin, and
B Clavel, and
C Verger, and
D Fritel
January 1974,
Anales espanoles de pediatria,
A Goupil, and
A Baglin, and
B Clavel, and
C Verger, and
D Fritel
November 1978,
Nihon Jinzo Gakkai shi,
A Goupil, and
A Baglin, and
B Clavel, and
C Verger, and
D Fritel
August 1974,
Deutsche medizinische Wochenschrift (1946),
A Goupil, and
A Baglin, and
B Clavel, and
C Verger, and
D Fritel
July 1978,
Revista medica de Chile,
A Goupil, and
A Baglin, and
B Clavel, and
C Verger, and
D Fritel
January 1974,
Langenbecks Archiv fur Chirurgie,
A Goupil, and
A Baglin, and
B Clavel, and
C Verger, and
D Fritel
July 1974,
Deutsche medizinische Wochenschrift (1946),
A Goupil, and
A Baglin, and
B Clavel, and
C Verger, and
D Fritel
December 1974,
MMW, Munchener medizinische Wochenschrift,
A Goupil, and
A Baglin, and
B Clavel, and
C Verger, and
D Fritel
July 1980,
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
A Goupil, and
A Baglin, and
B Clavel, and
C Verger, and
D Fritel
January 1980,
Sangre,
A Goupil, and
A Baglin, and
B Clavel, and
C Verger, and
D Fritel
November 1976,
Medizinische Klinik,
